Navigation Links
Cardium's Excellagen Assigned Q Code For Product Reimbursement
Date:12/4/2013

SAN DIEGO, Dec. 4, 2013 /PRNewswire/ -- Cardium Therapeutics (NYSE MKT: CXM) today announced that Cardium's Excellagen®, a wound care product indicated for the treatment of hard to heal wounds such as diabetic foot ulcers and pressure ulcers as well as other dermal wounds, has been assigned a new and unique, Level II HCPCS (Health Care Common Procedure Coding System) product reimbursement code, Q4149.  The Centers for Medicare and Medicaid Services (CMS) made their determination to assign Excellagen a Q code after review of Cardium's HCPCS Level II Code Modification Request and subsequent supporting information. This new reimbursement code takes effect January 1, 2014.

(Logo: http://photos.prnewswire.com/prnh/20051018/CARDIUMLOGO)

Excellagen is a syringe-based prescription-only product for treating a wide range of wounds that is applied weekly in the office or hospital outpatient setting by a licensed clinician.  This unique Q code is an important designation for providing a method for billing a product under Medicare and is utilized by many private payers as well.  Q code designations represent an important step forward for the reimbursement process under Medicare.

Cardium's submission to CMS focused on Excellagen's unique product formulation and format, as well as maintenance during manufacture of collagen's structural properties that support chemotaxis, cellular adhesion, migration and proliferation, and granulation tissue development.  The unique Q code assigned by CMS designates Excellagen as a single source product with a structural and functional role in providing a favorable wound healing environment.

"The Q code designation places Excellagen under the same code classification as well-known skin substitute wound care products such as Dermagraft®, Graftjacket® Xpress, EpiFix® and Inte
'/>"/>

SOURCE Cardium Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cardium Exhibiting Its New FDA-Cleared Excellagen® At The 2012 Spring Symposium Of Advanced Wound Care
2. Cardium Announces Agreement With UK-Based Angel Biomedical For Excellagen Supply And Planned European Market Expansion
3. Cardium Announces Plans For Commercializaton Of Excellagen® In The Russian Federation
4. Cardium Announces Excellagen Poster Presentatons At Desert Foot 9th Annual High Risk Diabetic Foot Conference
5. Cardium Receives ISO Certification for Excellagen
6. Cardium Announces Excellagen Presentation at the Symposium on Advanced Wound Care Spring 2013 Meeting
7. Cardium Reports On New Excellagen Distribution Agreement With AvKARE For Veterans Hospitals And Other Governmental Medical Facilities
8. Cardium Announces New Excellagen FDA 510(k) Submission Based On Expanded Structural And Functional Properties
9. Cardium Reports On Potential Use Of Excellagen To Repair Prenatally Diagnosed Birth Defects Using Mesenchymal Stem Cells
10. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
11. Sensitech Inc. Products Receive Regulatory Compliance Approval from IATA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014 Reportlinker.com announces that ... in its catalogue: ... Delivery Systems -- Focus on End Users ... STUDY OBJECTIVES A drug delivery ...
(Date:1/14/2014)... 14, 2014 HeartWare International, Inc . (NASDAQ: ... invasive, miniaturized circulatory support technologies that are revolutionizing the ... expects revenues for the fourth quarter of 2013 will ... to approximately $208 million. "Our full-year revenue ...
(Date:1/14/2014)... Jan. 14, 2014 Dynamic Healthcare Services, Inc. ("DHS"), a ... it acquired Progressive Home Medical Equipment, Inc. ("Progressive") of ... terms of the acquisition were not disclosed. ... providing a wide range of sleep, mobility, and respiratory products ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 2HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 3HeartWare International Announces Preliminary Fourth Quarter 2013 Revenues 4Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 2Dynamic Healthcare Services Completes Progressive Home Medical Equipment of Clarion, PA Investment 3
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), ... pipeline update webcast/conference call after the market closes on ... Officer, Vicente Anido, Jr., Ph.D., and Chief Financial Officer ... provide 2011 guidance, give a commercial and new product ...
... OSAKA, Japan, Dec. 21, 2010 Takeda Pharmaceutical ... its wholly-owned subsidiary, Takeda Pharmaceuticals North America, Inc. ... patent litigation brought against the companies in response ... generic ACTOS® (pioglitazone HCl), ACTO plus met® ...
Cached Medicine Technology:ISTA Pharmaceuticals Announces 2011 Guidance and Pipeline Update Webcast/Conference Call on January 5, 2011 2Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 2Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 3Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 4Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 5Takeda Completes Settlements With All Defendants in U.S. Patent Litigation Involving ACTOS® (pioglitazone HCI), ACTOplus met® (pioglitazone HCl and metformin HCl) and duetact® (pioglitazone HCl and glimepiride) 6
(Date:7/9/2014)... Researchers have found that fecal transplantation is ... in immunocompromised patients. This is the result of a ... the Center for Women,s Gastrointestinal Medicine at The Women,s ... published online in advance of print in the ... , or C. diff , has increased to ...
(Date:7/9/2014)... July 9, 2014 There has been a ... UT Southwestern Medical Center using MyChart, the online, interactive ... results, communicate with their healthcare providers, schedule appointments, and ... of patients actively using MyChart each year ... year increased more than 10-fold, according to a study ...
(Date:7/9/2014)... Diseases (NIAID), part of the National Institutes of ... CRS3123, an investigational oral antibiotic intended to treat ... infection. CRS3123 (previously known as REP3123) is a ... sparing normal intestinal bacteria. , The Phase I ... and women ages 18 to 45 in a ...
(Date:7/9/2014)... , , , , , , , , ... , , , , , ... gunshot is a binaural recording using KEMAR, the weapon was an SA80 assault rifle and the microphone is 50m downrange from the firer and approximately 30cm ... , , , , , ... , , , , , ...
(Date:7/8/2014)... Restoration has been awarded up to $15 million by ... four -year project aiming to help brain-injured people restore ... neurosurgery, engineering, neurobiology, psychology and physics will collaborate to ... the brain. , Memory is the process in which ... store it and retrieve it. Certain types of illnesses ...
Breaking Medicine News(10 mins):Health News:Women's Medicine Collaborative examines safety of fecal transplant to treat C. difficile 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 2Health News:MyChart use skyrocketing among cancer patients, UT Southwestern study finds 3Health News:NIH launches Phase I clinical trial of novel drug to treat Clostridium difficile infection 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 2Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 3Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 4Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 5Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 6Health News:Fit for the frontline? New study identifies the hearing requirements of British soldiers 7Health News:DARPA awards UCLA $15 million to restore lost memory 2Health News:DARPA awards UCLA $15 million to restore lost memory 3
... 40th Annual Meeting on Women,s Cancer Proves Superiority of ... 11 New data presented on Saturday during the ... Annual Meeting on Women,s Cancer demonstrated the accuracy of ... test results and the Risk of Ovarian Malignancy Algorithm ...
... FY 2008 % change ... ------- -------- ------- ... +3.6%, Adjusted net income, excluding selected, items(1): ... Adjusted EPS excluding EUR5.49 +6.2% EUR1.25 ...
... Combination With Herceptin and Taxotere Will Become Decision ... a New Report from Decision ResourcesWALTHAM, Mass., Feb. ... leading research and advisory firms for pharmaceutical and ... approved in combination with emerging therapies, it will ...
... More Than 15% of Total RevenuesCHICAGO, Feb. 11 ... (OTC Bulletin Board: CGSY)), the world,s leading telecommunications ... its 2009 sales strategy will include a special ... vertical market, which represents more than 15% of ...
... to discuss recent findings showing that health-related ... and pharmacy costs-- Presentation includes real-world insights ... to develop integrated health and productivity enhancements ... and musculoskeletal disorders are significant cost drivers ...
... CLARA, Calif., Feb. 11 Samplify Systems, Inc., a ... today announced the selection of its SAM1600 family of ... real-time signal-compression technology, as a finalist in EDN ... The prestigious Innovation Awards honor the ...
Cached Medicine News:Health News:Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 2Health News:Biomarker Combination and Risk of Ovarian Malignancy Algorithm (Roma(TM)) Demonstrates Accuracy in Detecting Ovarian Cancer 3Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 2Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 3Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 4Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 5Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 6Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 7Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 8Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 9Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 10Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 11Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 12Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 13Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 14Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 15Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 16Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 17Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 18Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 19Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 20Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 21Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 22Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 23Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 24Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 25Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 26Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 27Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 28Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 29Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 30Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 31Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 32Health News:Sanofi-aventis Delivers 2008 Results Above Guidance 33Health News:If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer 2
Preclude Dura Substitute is the only non-biological membrane designed to "seal" around suture holes. 0.3 mm as nominal thickness....
... synthetic absorbable implant for the bridging of Dura ... is pliable, regardless of being used dry or ... must be taken, while implanting, to ensure that ... is oriented towards the cortex or the spinal ...
... is a non-absorbable dura ... purified polyesterurethane. Its microporous ... of fibroblast, supporting tissue ... minimizes suture channels, resulting ...
The Bovie IDS Series are the latest electrosurgical generators with fully digital implementation....
Medicine Products: